![](https://investorshub.advfn.com/uicon/718277.png?cb=1571665667)
Monday, September 02, 2019 6:31:27 AM
What the Co-Founder emailed me has been rattling around in my mind.. where he stated basically 4 stages of product types(some with overlaps) and ending up next year considering if and how to proceed in the 4th stage, Pharmaceutical applications.
As mentioned there are different procedures for different molecules('CBDs') and seeds/seed shells in particular for one potential that I am very interested in seeing developed.. the Isolate would be more valuable by a long ways than general Isolation.. exists in lower concentrations than ''General'.
This led me to look at Pharmas, and looking at the JV 'Dragonfly. Where I found Dragonfly as two advisory Board members that have associations with Novartis International AG and Glaxosmithkline pharmaceuticals.
GlaxoSmithKline Plc and Pfizer Inc. is studying CBD..
Novartis, through its generic drug arm Sandoz, has signed an agreement with Tilray Canada to distribute medical cannabis products in countries where it is—or will be—legal.
I suspect these two Pharmas have Advisors at Dragonfly for pertinent reasons.
Such is the depth and breath for Stil's future.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM